Detection of germline BRCA1 mutations by multiple-dye cleavase fragment length polymorphism (MD-CFLP) method

被引:2
作者
Casadei, S
Cortesi, L
Pensotti, V
Radice, P
Pierotti, M
Amadori, D
Calistri, D [1 ]
机构
[1] Ist Oncol Romagnolo, I-47100 Forli, Italy
[2] Morgagni Pierantoni Hosp, Dept Med Oncol, I-47100 Forli, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
关键词
mutational analysis; hereditary breast cancer; BRCA1; CFLP;
D O I
10.1054/bjoc.2001.1988
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We describe the Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method set up for a sensitive and preliminary rapid screening of BRCA1 mutations. We analysed exons 11 and 16, which are known to cover slightly more than 70% of the whole coding region of the gene, subdivided into 4 amplicons and labelled with different fluorescent dUTPs. MD-CFLP was first utilised on a panel of 30 DNA samples in which the presence of single-base substitutions or small deletions/insertions had been previously identified by direct sequencing as gold standard, in order to define the optimal conditions in terms of PCR amplification and temperature of digestion. In a second step, we blindly analysed 21 DNA samples by MD-CFLP to verify its reliability. The sensitivity and specificity of MD-CFLP were both 100% in the first study, and 80% and 94%, respectively, in the blind sample assay. Our results demonstrate the capability of the MD-CFLP method to detect DNA sequence alterations in fragments of more than 1 kb. We conclude that CFLP is a powerful tool in mutational analysis, offering reliable results in a shorter time and at a lower cost than conventional methods, and its potential can be enhanced when internal fluorescent labelling and laser detection are used. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:845 / 849
页数:5
相关论文
共 18 条
[1]   Differentiation of bacterial 16S rRNA genes and intergenic regions and Mycobacterium tuberculosis katG genes by structure-specific endonuclease cleavage [J].
Brow, MAD ;
Oldenburg, MC ;
Lyamichev, V ;
Heisler, LM ;
Lyamicheva, N ;
Hall, JG ;
Eagan, NJ ;
Olive, DM ;
Smith, LM ;
Fors, L ;
Dahlberg, JE .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (12) :3129-3137
[2]  
Eisinger F, 1998, CANCER RES, V58, P1588
[3]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[4]   CONFIRMATION OF BRCA1 LAY ANALYSIS OF GERMLINE MUTATIONS LINKED TO BREAST AND OVARIAN-CANCER IN 10 FAMILIES [J].
FRIEDMAN, LS ;
OSTERMEYER, EA ;
SZABO, CI ;
DOWD, P ;
LYNCH, ED ;
ROWELL, SE ;
KING, MC .
NATURE GENETICS, 1994, 8 (04) :399-404
[5]   The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews [J].
Hartge, P ;
Struewing, JP ;
Wacholder, S ;
Brody, LC ;
Tucker, MA .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (04) :963-970
[6]   RAPID DETECTION OF BRCA1 MUTATIONS BY THE PROTEIN TRUNCATION TEST [J].
HOGERVORST, FBL ;
CORNELIS, RS ;
BOUT, M ;
VANVLIET, M ;
OOSTERWIJK, JC ;
OLMER, R ;
BAKKER, B ;
KLIJN, JGM ;
VASEN, HFA ;
MEIJERSHEIJBOER, H ;
MENKO, FH ;
CORNELISSE, CJ ;
DENDUNNEN, JT ;
DEVILEE, P ;
VANOMMEN, GJB .
NATURE GENETICS, 1995, 10 (02) :208-212
[7]  
Maddox LO, 1997, BIOCHEM MOL BIOL INT, V43, P1163
[8]   Determination of hepatitis C virus genotypes in the United States by Cleavase Fragment Length Polymorphism analysis [J].
Marshall, DJ ;
Heisler, LH ;
Lyamichev, V ;
Murvine, C ;
Olive, DM ;
Ehrlich, GD ;
Neri, BP ;
deArruda, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (12) :3156-3162
[9]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[10]   Genetic testing for cancer risk [J].
Ponder, B .
SCIENCE, 1997, 278 (5340) :1050-1054